{"nct_id":"NCT06082167","title":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-08","start_date":"2024-06-07","start_date_type":"ACTUAL","primary_completion_date":"2028-08","primary_completion_date_type":"ESTIMATED","completion_date":"2029-03","completion_date_type":"ESTIMATED","phases":["PHASE2","PHASE3"],"tickers":["EXEL"]}